| Jesus Gabriel Martinez, OD | |
|
3515 Saint Rose Pkwy Ste 110, Henderson, NV 89052-4596 | |
| (702) 848-3387 | |
| (702) 848-3778 |
| Full Name | Jesus Gabriel Martinez |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 8 Years |
| Location | 3515 Saint Rose Pkwy Ste 110, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942754155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1010 (Nevada) | Primary |
| Provider Name | Eye Associates Of Nevada |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801843685 PECOS PAC ID: 6002894680 Enrollment ID: O20040709001181 |
News Archive
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
A team at the Stanford University School of Medicine has cataloged, down to the letter, exactly what parts of the genetic code are essential for survival in one bacterial species, Caulobacter crescentus.
Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.
› Verified 9 days ago
| Provider Name | Dr Martinez Od Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366040305 PECOS PAC ID: 6305266693 Enrollment ID: O20201027001207 |
News Archive
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
A team at the Stanford University School of Medicine has cataloged, down to the letter, exactly what parts of the genetic code are essential for survival in one bacterial species, Caulobacter crescentus.
Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jesus Gabriel Martinez, OD 3515 Saint Rose Pkwy Ste 110, Henderson, NV 89052-4596 Ph: (702) 848-3387 | Jesus Gabriel Martinez, OD 3515 Saint Rose Pkwy Ste 110, Henderson, NV 89052-4596 Ph: (702) 848-3387 |
News Archive
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that.
A team at the Stanford University School of Medicine has cataloged, down to the letter, exactly what parts of the genetic code are essential for survival in one bacterial species, Caulobacter crescentus.
Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.
› Verified 9 days ago
Dr. Aaron Mancuso, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2461 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-636-2020 Fax: 702-616-2133 | |
Dr. Angela Khakshooy, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 2703 Peekskill Ave, Henderson, NV 89052 Phone: 310-804-4468 | |
Nancy Tran Phan Gauthier, OD Optometrist Medicare: Medicare Enrolled Practice Location: 695 S Green Valley Pkwy, Henderson, NV 89052 Phone: 702-407-2455 | |
Braden Sorensen Od Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 680 S Green Valley Pkwy Ste 120, Henderson, NV 89052 Phone: 702-889-3937 | |
Kimberly Le Od Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 300 E Lake Mead Pkwy, Henderson, NV 89015 Phone: 858-348-7790 | |
Dr. Joseph Lao, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 543 N Stephanie St Ste 110, Henderson, NV 89014 Phone: 702-888-1079 Fax: 702-333-1016 | |
Trang Tam Tran, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 540 Marks St, Henderson, NV 89014 Phone: 702-434-2441 Fax: 702-434-6409 |